Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 4/20 | 0.47 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20217280 | 0.98 | KCNA5 (0.44) | KCNA5KCNE1KDM4ESLC6A4ALDH1A1 | |
| SCHEMBL12789439 | 0.98 | KCNA5 (0.44) | KCNA5KCNE1KDM4ESLC6A4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL15400020 | 0.96 | KCNA5 (0.43) | KCNA5KCNE1KDM4ESLC6A4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL15400032 | 0.96 | KCNA5 (0.43) | KCNA5KCNE1KDM4ESLC6A4ALDH1A1 | |
| SCHEMBL14862495 | 0.95 | KCNA5 (0.44) | KCNA5KCNE1KDM4ESLC6A4ALDH1A1 | |
| SCHEMBL14862575 | 0.91 | SLC6A4 (0.44) | KCNA5KCNE1KDM4ESLC6A4ALDH1A1 | |
| SCHEMBL14862093 | 0.91 | SLC6A4 (0.44) | KCNA5KCNE1KDM4ESLC6A4ALDH1A1 | |
| SCHEMBL2085504 | 0.91 | SLC6A4 (0.44) | KCNA5KCNE1KDM4ESLC6A4ALDH1A1 | |
| SCHEMBL29779604 | 0.91 | SLC6A4 (0.44) | KCNA5KCNE1KDM4ESLC6A4ALDH1A1 | |
| SCHEMBL29779595 | 0.91 | SLC6A4 (0.44) | KCNA5KCNE1KDM4ESLC6A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233799-B1 | DOPAMINE D2 RECEPTOR LIGANDS | BROAD INST INC (US) | 2021-05-19 | — | — | EP | disclosed |
| EP-3233799-B1 | DOPAMINE D2 RECEPTOR LIGANDS | BROAD INST INC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-10752588-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10752588-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190345105-A9 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2019-11-14 | — | — | US | disclosed |
| US-20190345105-A9 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2019-11-14 | — | — | US | disclosed |
| US-20190023656-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2019-01-24 | — | — | US | disclosed |
| US-20190023656-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2019-01-24 | — | — | US | disclosed |
| EP-2766352-B1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIV HEALTH NETWORK UHN (CA) | 2018-06-06 | — | — | EP | disclosed |
| EP-3233799-A1 | DOPAMINE D2 RECEPTOR LIGANDS | The Broad Institute Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2952503-A1 | HIV REPLICATION INHIBITOR | Shionogi & Co., Ltd. (JP) | 2015-12-09 | — | — | EP | disclosed |
| WO-2015156421-A1 | DIHYDROTHIAZINE AND DIHYDROOXAZINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2015-10-15 | — | — | WO | disclosed |
| US-20140371202-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2014-12-18 | — | — | US | disclosed |
| EP-2752410-A1 | HETEROCYCLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY | Shionogi & Co., Ltd. (JP) | 2014-07-09 | — | — | EP | disclosed |
| WO-2014065434-A1 | DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2014-05-01 | — | — | WO | disclosed |
| WO-2013001830-A1 | NUCLEOSIDE ANTIBIOTIC DERIVATIVE | 国立大学法人北海道大学 (JP) | 2013-01-03 | — | — | WO | disclosed |
| EP-0920424-B1 | NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2005-11-30 | — | — | EP | disclosed |
| US-6194437-B1 | ANTIDEPRESSANTS; ANTICANCER AGENTS; GASTROINTESTINAL DISORDERS; COGNITION ACTIVATORS | WARNER-LAMBERT COMPANY | 2001-02-27 | — | — | US | disclosed |
| EP-0920424-A1 | NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-06-09 | — | — | EP | disclosed |
| WO-1998007718-A1 | NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345105-A9 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, SLC6A3, NTSR2 | KCNA5 1071/4885KCNE1 1097/4885KDM4E 4204/4885 |
| US-20190023656-A1 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, SLC6A3, NTSR2 | KCNA5 1071/4885KCNE1 1097/4885KDM4E 4204/4885 |
| US-20140371202-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | PLK4, PLK2, PLK3 | KCNA5 2880/4885KCNE1 1855/4885KDM4E 1467/4885 |
| US-10752588-B2 | Dopamine D2 receptor ligands | DRD2, SLC6A3, NTSR2 | KCNA5 1071/4885KCNE1 1097/4885KDM4E 4204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.